🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "major milestone" in the fight against drug-resistant strains of the bacteria, according to scientists.

A Worldwide Challenge

The sexually transmitted infection are on the rise around the world, with data suggesting over 82 million infections each year. Especially elevated rates are reported in the African continent and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. In England, cases have hit a historical peak, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary step in the face of growing infection rates, increasing antimicrobial resistance and the extremely scarce available drugs at this time.”

Medical experts are particularly alarmed about the rise in drug-resistant strains. The WHO has listed it as a "priority pathogen". Recent surveillance revealed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Drugs Gain Approval

One new antibiotic, marketed under the name a brand name, was cleared by the American regulatory agency in recent days for use against gonorrhoea. This STI can lead to significant complications, including infertility. Scientists believe that focused deployment of this new drug will help hinder the emergence of superbugs.

Gepotidacin, developed by the drugmaker GSK, gained clearance in concurrent days. This treatment, which is employed against UTIs, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment stemmed from a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to see it through.

“This milestone signifies a significant shift in the therapy of highly resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Testing Results and Worldwide Availability

According to data published in a major medical journal, zoliflodacin eradicated the vast majority of genital gonorrhoea infections. This places it at an equal footing with the existing first-line therapy, which combines a dual-drug approach. The trial included over 900 participants from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, GARDP has the ability to make available and distribute the drug in numerous low-income and middle-income countries.

Clinicians on the front lines have expressed hope. The availability of a single-dose, oral treatment like this is described as a "revolutionary step" for public health efforts. This is viewed as essential to alleviate the strain of the disease for individuals and to stop the proliferation of extremely resistant gonorrhoea around the world.